FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

The FDA re­ject­ed Rock­et Phar­ma­ceu­ti­cals’ gene ther­a­py for leuko­cyte ad­he­sion de­fi­cien­cy-I (LAD-I), re­quest­ing “lim­it­ed ad­di­tion­al” man­u­fac­tur­ing in­for­ma­tion.

The com­pa­ny an­nounced the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER